Is TEVAR really needed for uncomplicated type B aortic dissection?

Area of Science:

• Cardiovascular Surgery
• Vascular Surgery
• Interventional Cardiology

Background:

• Thoracic endovascular aortic repair (TEVAR) is a primary treatment for acute aortic dissection, particularly complicated Stanford Type B dissections (co-TBAD).
• Optimal medical therapy (OMT) manages uncomplicated Type B aortic dissections (un-TBAD), but these patients risk disease progression.
• The comparative cost-benefit and clinical outcomes of TEVAR for both un-TBAD and co-TBAD require investigation.

Purpose of the Study:

• To systematically review and meta-analyze clinical outcomes of TEVAR in patients with complicated and uncomplicated Type B aortic dissections.
• To compare in-hospital mortality, long-term survival, and postoperative complications between TEVAR for co-TBAD and un-TBAD.

Main Methods:

• Systematic review and meta-analysis of existing studies.
• Inclusion of data on clinical outcomes, mortality rates, and postoperative complications such as stroke, renal failure, and endoleak.

Main Results:

• No significant difference in in-hospital mortality or 5-year survival between TEVAR for un-TBAD and co-TBAD.
• Higher 30-day mortality observed in the co-TBAD cohort.
• Co-TBAD patients had increased risk of postoperative stroke and TEVAR endoleak; un-TBAD patients had higher risk of postoperative renal failure.

Conclusions:

• TEVAR demonstrates comparable long-term survival for both complicated and uncomplicated Type B aortic dissections.
• Distinct postoperative complication profiles exist for TEVAR in co-TBAD versus un-TBAD.
• Further prospective studies are recommended to clarify comparative efficacies and optimize patient management strategies.